Classic immunohistochemistry markers such as expression of estrogen (ER), progesterone (PG), and human epidermal growth factor (HER2) receptors; and clinicopathological factors, like tumor grade, size, nodal involvement, are conventionally used to select therapy and to predict disease progression. This evidence concerns the gene ESR1 and neoplasm.